Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema

NCT02079688 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild to Moderate Atopic Dermatitis

Interventions

DRUG: SB011, 2 % (Water/Oil/Water) emulsion of hgd40
DRUG: Multiple W/O/W formulation, active ingredient-free vehicle

Sponsor

Sterna Biologicals GmbH & Co. KG